The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events.

Trial Profile

The Association Between Dopamine Agonists and Cardiac Valvulopathy, Fibrosis and Other Cardiopulmonary Events.

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2011

At a glance

  • Drugs Cabergoline; Dopamine receptor agonists; Levodopa
  • Indications Hyperprolactinaemia; Parkinson's disease
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Jan 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top